Enlivex Receives Regulatory Authorization From Israel's Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis [Yahoo! Finance]
Enlivex Therapeutics Ltd. - Ordinary Shares (ENLV)
Company Research
Source: Yahoo! Finance
Medicines temporarily decrease pain but don't help with the inflammatory chronic condition and the chronic pain comes back again, while physical therapy rarely works as well as we hope it will. For some, the cause of this debilitating knee pain that can cause mobility issues is osteoarthritis in the knee , which makes it painful to jog, run, climb stairs or kneel. Over time, osteoarthritis of the knee symptoms can become more drastic, changing the shape of patients' knees and making their joints feel wobbly. Treatment can include surgery, but most healthcare providers attempt non-surgical treatments like physical therapy, knee braces and pain medications before recommending surgery. A new cell therapy could provide patients with another option. In January , the Israeli Ministry of Health (IMOH) authorized the initiation of a new trial for Allocetra TM , a groundbreaking cell therapy that could help treat osteoarthritis patients. Sponsored by clinical-stage macrophage reprogram
Show less
Read more
Impact Snapshot
Event Time:
ENLV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ENLV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ENLV alerts
High impacting Enlivex Therapeutics Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
ENLV
News
- Enlivex Therapeutics Ltd. (NASDAQ: ENLV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.MarketBeat
- Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee OsteoarthritisGlobeNewswire
- Enlivex Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis [Yahoo! Finance]Yahoo! Finance
- Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee OsteoarthritisGlobeNewswire
- Enlivex (ENLV) Stock Plummets 51% in a Week: Here's Why [Yahoo! Finance]Yahoo! Finance
ENLV
Analyst Actions
- 4/23/24 - HC Wainwright
ENLV
Sec Filings
- 4/22/24 - Form 6-K
- 4/16/24 - Form 6-K
- 3/29/24 - Form 6-K
- ENLV's page on the SEC website